-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Cerevel Therapeutics Holdings, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q1 2024.
- Cerevel Therapeutics Holdings, Inc. Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $138K, a 62.4% increase year-over-year.
- Cerevel Therapeutics Holdings, Inc. Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was $556K.
- Cerevel Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2023 was $503K, a 214% increase from 2022.
- Cerevel Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2022 was $160K.
- Cerevel Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2020 was -$24K, a 153% decline from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)